Article

Florida Cancer Specialists Researcher First-Authored SABCS Breast Cancer Study

A member of the clinical research team at Florida Cancer Specialists & Research Institute is to be a first author for a breast cancer study to be presented at San Antonio Breast Cancer Symposium.

Fort Myers, Florida — Medical oncologist Manish R. Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as the first author of a study examining dose escalation of an oral complete estrogen receptor antagonist/selective ER degrader in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.

Entitled, “Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer,” the study was shared at the San Antonio Breast Cancer Symposium held Dec. 7-12, 2021.

While still ongoing, the study’s analysis indicates an evolution in the standard of care, to include complete estrogen receptor antagonists.

Learn more.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Dr Margrit Wiesendanger
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo